Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

AYTU vs CAPR: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CAPR Captures Overall Composite Edge (28.0 SELL vs 48.9 HOLD), While AYTU Leads 4–2 on Growth & Valuation Pillars

CAPR Overall Winner 6-Pillar Tally: AYTU 4 – 2 CAPR Matrix Metrics: AYTU 6 – 4 CAPR

As of Nov 16, 2026, Capricor Therapeutics Inc (CAPR) captures the overall head-to-head institutional edge over AYTU BioPharma, Inc. (AYTU) on higher Unified Composite conviction (28.0/100 SELL vs. 48.9/100 HOLD) after splitting the core matrix 4–6 (led by Profitability & Quality, Options & Positioning), while AYTU wins 4–2 across the 6-pillar growth and valuation breakdown. AYTU trades at $1.81 (9.2x Forward P/E, -14.4% operating margin) versus CAPR at $8.47 (78.7x Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While AYTU currently prints a higher short-term Unified Composite Score (48.9/100 HOLD vs. CAPR 28.0/100 SELL), CAPR captures the overall institutional head-to-head verdict (4–6 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -14.4% operating margin) and revenue trajectory (-7.9% vs. +6.4% YoY).
  • Technical & Structure Timing Caution: AYTU is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.7); meanwhile CAPR trades in a Markup technical trend (CONSOLIDATION options phase, RSI 51.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AYTU vs CAPR
AYTU NASDAQ
AYTU BioPharma, Inc. Common Stock
Pharmaceutical Preparations
$1.81
+1.69% 1D
Market Cap $19.6M
TTM Revenue $58M
Forward P/E 9.2x
Beta / 30D Vol 0.65β · 35% Vol
Unified Composite Score
48.9 / 100 HOLD
Tech 49.0 Fund 53.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -7.8%), weak momentum, RSI 38
RSI-14: 37.7 · SMA20: $1.89 · SMA50: $2.00
CAPR NASDAQ Head-to-Head Winner
Capricor Therapeutics Inc
Pharmaceutical Preparations
$8.47
-11.12% 1D
Market Cap $595.4M
TTM Revenue $11M
Forward P/E 78.7x
Beta / 30D Vol 1.52β · 152% Vol
Unified Composite Score
28.0 / 100 SELL
Tech 50.0 Fund 37.0 Flow 68.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (1.2% over 20 days), RSI 51
RSI-14: 51.3 · SMA20: $7.79 · SMA50: $8.08

6-Pillar Scorecard Institutional Category Breakdown (AYTU 4 – 2 CAPR)

Columns: Metric · AYTU · CAPR
1. Valuation Multiples AYTU
Forward P/E 9.2x 78.7x
Trailing P/E 9.2x 78.7x
PEG Ratio N/M 0.38x
EV / Revenue 0.3x 57.8x
2. Growth & Scale AYTU
Revenue Growth (YoY) +6.4% -7.9%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $58M $11M
Market Cap $19.6M $595.4M
3. Profitability & Quality CAPR
Gross Margin 64.0% N/A
Operating Margin -14.4% 0.0%
Net Profit Margin -24.8% 0.0%
Return on Equity (ROE) -52.5% -100.5%
4. Balance Sheet & Cash Flow AYTU
Cash Generation (TTM) -$1.4M -$146M
Cash Flow Margin -2.4% N/A
Net Cash / Leverage $4.9M Net Cash $48M Net Debt (0.44x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CAPR
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile N/A (N/A) 637.1% (89th %ile)
Put/Call OI Skew N/A 1.57x (Put-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown ACCUMULATION · Markup
6. R&D & Supply-Chain Moat AYTU
OpEx & R&D Intensity 78.4% of Rev ($45M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Drug Manufacturers - Specialty & Generic Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AYTU (6) vs CAPR (4)
Institutional Metric AYTU CAPR Criterion Row Edge
Market Capitalization
Scale
$19.6M $595.4M Larger Scale CAPR
Trailing P/E Ratio
Valuation
9.2x 78.7x Lower Multiple AYTU
Forward P/E Ratio
Valuation
9.2x 78.7x Lower Multiple AYTU
Revenue Growth (YoY)
Growth
+6.4% -7.9% Higher Growth AYTU
Operating Margin (TTM)
Profitability
-14.4% 0.0% Higher Margin CAPR
Net Profit Margin
Profitability
-24.8% 0.0% Higher Margin CAPR
Return on Equity (ROE)
Capital Efficiency
-52.5% -100.5% Higher ROE AYTU
52-Week Range Position
Momentum
5% ($2–$3) 15% ($3–$40) Stronger Trend CAPR
Beta / 30D Volatility
Risk Regime
0.65β · 35% Vol 1.52β · 152% Vol Lower Realized Risk AYTU
Unified Institutional Score
Composite Signal
48.9 / 100 (HOLD) 28.0 / 100 (SELL) Higher Composite AYTU
Trailing 12M Revenue (USD)
Operating Scale
$58M $11M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
64.0% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.3x EV/Rev 0.38x PEG · 57.8x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$1.4M ($4.9M Net Cash) -$146M ($48M Net Debt (0.44x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CAPR +37.5 pp
AYTU: -11.27% · CAPR: +26.23%
3M Horizon CAPR +42.94 pp
AYTU: -23.31% · CAPR: +19.63%
6M Horizon AYTU +53.23 pp
AYTU: -17.35% · CAPR: -70.58%
1Y Horizon CAPR +58.93 pp
AYTU: -12.14% · CAPR: +46.79%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period AYTU Revenue CAPR Revenue AYTU Op. Margin CAPR Op. Margin Margin Leader
FY2019 $10M $0M -230.1% -769.5% AYTU
FY2020 $30M $0M -76.5% -4412.6% AYTU
FY2021 $70M $0M -89.7% -8549.9% AYTU
FY2022 $100M $0M -113.7% -1163.9% AYTU
FY2023 $110M $30M -15.9% -95.6% AYTU
FY2024 $70M $20M -2.4% -191.1% AYTU
FY2025 $70M N/A -11.8% N/A AYTU
FY2026 $60M N/A -14.4% N/A AYTU

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AYTU UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AYTU Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CAPR CONSOLIDATION
56d in phase · OBV ACCUMULATION
Current IV 637.1%
IV Percentile 89th %ile
Put/Call OI Skew 1.57x (Put-Skewed)
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact CAPR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AYTU Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $19.6M market capitalization and -14.4% operating margin.
OpEx & R&D Reinvestment 78.4% of Rev ($45M)
90D Engineering Disclosures 0 Published
CAPR Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $595.4M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ AYTU vs CAPR Key Questions & Quantitative Answers

As of Nov 16, 2026, Capricor Therapeutics Inc (CAPR) captures the overall head-to-head institutional edge over AYTU BioPharma, Inc. (AYTU) on higher Unified Composite conviction (28.0/100 SELL vs. 48.9/100 HOLD) after splitting the core matrix 4–6 (led by Profitability & Quality, Options & Positioning), while AYTU wins 4–2 across the 6-pillar growth and valuation breakdown. AYTU trades at $1.81 (9.2x Forward P/E, -14.4% operating margin) versus CAPR at $8.47 (78.7x Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While AYTU currently prints a higher short-term Unified Composite Score (48.9/100 HOLD vs. CAPR 28.0/100 SELL), CAPR captures the overall institutional head-to-head verdict (4–6 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -14.4% operating margin) and revenue trajectory (-7.9% vs. +6.4% YoY). Technical & Structure Timing Caution: AYTU is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.7); meanwhile CAPR trades in a Markup technical trend (CONSOLIDATION options phase, RSI 51.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

AYTU leads the Growth & Scale pillar: AYTU posts +6.4% YoY revenue growth and +0.0% YoY earnings growth on $58M TTM revenue (64.0% gross margin, -14.4% operating margin), compared with CAPR at -7.9% YoY revenue growth and +0.0% YoY earnings growth on $11M TTM revenue (N/A gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2019 to FY2026), AYTU cumulative revenue shifted +500.0% while CAPR shifted -33.3%. In operating R&D and SG&A reinvestment, AYTU deploys 78.4% of Rev ($45M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CAPR.

AYTU screens cheaper on headline valuation multiples. AYTU trades at 9.2x Forward P/E, 9.2x Trailing P/E, N/M PEG, and 0.3x EV/Revenue (-2.4% FCF margin), whereas CAPR trades at 78.7x Forward P/E, 78.7x Trailing P/E, 0.38x PEG, and 57.8x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AYTU (-52.5% ROE) versus CAPR (-100.5% ROE) capital efficiency.

In options market volatility and institutional positioning, AYTU carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.65β · 35% Vol realized risk). By comparison, CAPR carries 637.1% implied volatility (89th %ile, Extreme (>80th %ile)), a 1.57x (Put-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.52β · 152% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.